Proteomic approaches for serum biomarker discovery in cancer.

Monitoring the protein expression pattern in tumour cells by proteomics technologies offers opportunities to discover potentially new biomarkers for the early detection and diagnosis of cancer. Different proteomic tools such as 2D-PAGE, 2D-DIGE, SELDI-ToF-MS technology, protein arrays, ICAT, iTRAQ and MudPIT have been used for differential analysis of various biological samples, including cell lysates, cell secretome (conditioned medium), serum, plasma, tumour tissue and nipple aspirate fluid, to better understand the molecular basis of cancer pathogenesis and the validation and characterisation of disease-associated proteins. In recent years, there has been a large increase in cancer-related publications dealing with new biomarker discovery for cancer, therefore, in this review we have focused on the contribution of proteomics technologies in serum and conditioned medium-based oncology research particularly for lung, breast, melanoma and pancreatic cancer.

[1]  Peng-Fei Zhang,et al.  Proteomics-based identification of secreted protein dihydrodiol dehydrogenase as a novel serum markers of non-small cell lung cancer. , 2006, Lung cancer.

[2]  H. Kato,et al.  Plasma proteomics of lung cancer by a linkage of multi‐dimensional liquid chromatography and two‐dimensional difference gel electrophoresis , 2006, Proteomics.

[3]  Michelle A. Anderson,et al.  Comparative serum glycoproteomics using lectin selected sialic acid glycoproteins with mass spectrometric analysis: application to pancreatic cancer serum. , 2006, Journal of proteome research.

[4]  Brian Leyland-Jones,et al.  A systems approach to clinical oncology: Focus on breast cancer , 2006, Proteome Science.

[5]  A. Jemal,et al.  Cancer Statistics, 2006 , 2006, CA: a cancer journal for clinicians.

[6]  Laurence Lodé,et al.  Surface‐enhanced laser desorption/ionization time of flight mass spectrometry protein profiling identifies ubiquitin and ferritin light chain as prognostic biomarkers in node‐negative breast cancer tumors , 2006, Proteomics.

[7]  Wendy Frankel,et al.  Fibrinogen gamma overexpression in pancreatic cancer identified by large-scale proteomic analysis of serum samples. , 2006, Cancer research.

[8]  F. Bertucci,et al.  Postoperative serum proteomic profiles may predict metastatic relapse in high-risk primary breast cancer patients receiving adjuvant chemotherapy , 2006, Oncogene.

[9]  Carole Mathelin,et al.  Serum biomarkers for detection of breast cancers: a prospective study , 2006, Breast Cancer Research and Treatment.

[10]  Xiao-Ying Meng,et al.  Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. , 2005, Clinical chemistry.

[11]  Tomoko Umaki,et al.  Possible detection of pancreatic cancer by plasma protein profiling. , 2005, Cancer research.

[12]  R. Gelber,et al.  Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[13]  A. Rustgi,et al.  Characterization of proteins in human pancreatic cancer serum using differential gel electrophoresis and tandem mass spectrometry. , 2005, Journal of proteome research.

[14]  J. Richie,et al.  Chromatofocusing fractionation and two‐dimensional difference gel electrophoresis for low abundance serum proteins , 2005, Proteomics.

[15]  Jiekai Yu,et al.  SELDI-TOF-MS: the proteomics and bioinformatics approaches in the diagnosis of breast cancer. , 2005, Breast.

[16]  I. Dryden,et al.  Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  Wei Zhang,et al.  Application of serum SELDI proteomic patterns in diagnosis of lung cancer , 2005, BMC Cancer.

[18]  R. Zhong,et al.  Proteomics-based identification of DEAD-box protein 48 as a novel autoantigen, a prospective serum marker for pancreatic cancer. , 2005, Biochemical and biophysical research communications.

[19]  B. Martin,et al.  Peptide profiling in epithelial tumor plasma by the emerging proteomic techniques. , 2005, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

[20]  N. Viñolas,et al.  Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer. , 2005, Anticancer research.

[21]  T. Colgan,et al.  Search for cancer markers from endometrial tissues using differentially labeled tags iTRAQ and cICAT with multidimensional liquid chromatography and tandem mass spectrometry. , 2005, Journal of proteome research.

[22]  H. Kato,et al.  Clinical‐scale high‐throughput human plasma proteome analysis: Lung adenocarcinoma , 2005, Proteomics.

[23]  Emanuel F Petricoin,et al.  Importance of communication between producers and consumers of publicly available experimental data. , 2005, Journal of the National Cancer Institute.

[24]  I. Ellis,et al.  The Nottingham prognostic index in primary breast cancer , 2005, Breast Cancer Research and Treatment.

[25]  K. Parker,et al.  Multiplexed Protein Quantitation in Saccharomyces cerevisiae Using Amine-reactive Isobaric Tagging Reagents*S , 2004, Molecular & Cellular Proteomics.

[26]  Lisa H. Cazares,et al.  Surfaced-Enhanced Laser Desorption/Ionization Time-of-Flight (SELDI-TOF) Differentiation of Serum Protein Profiles of BRCA-1 and Sporadic Breast Cancer , 2004, Annals of Surgical Oncology.

[27]  M. Guan,et al.  Tree analysis of mass spectral urine profiles discriminates transitional cell carcinoma of the bladder from noncancer patient. , 2004, Clinical biochemistry.

[28]  Eric R Siegel,et al.  Diagnosis of pancreatic cancer using serum proteomic profiling. , 2004, Neoplasia.

[29]  D. Morton,et al.  Detection of Differentially Expressed Proteins in Early‐Stage Melanoma Patients Using SELDI‐TOF Mass Spectrometry , 2004, Annals of the New York Academy of Sciences.

[30]  M Paesmans,et al.  CYFRA 21-1 is a prognostic determinant in non-small-cell lung cancer: results of a meta-analysis in 2063 patients , 2004, British Journal of Cancer.

[31]  A. Chambers,et al.  Role of osteopontin in tumour progression , 2004, British Journal of Cancer.

[32]  E. Diamandis.  Mass Spectrometry as a Diagnostic and a Cancer Biomarker Discovery Tool , 2004, Molecular & Cellular Proteomics.

[33]  J. Mancini,et al.  Prognostic value of combination of Cyfra 21-1, CEA and NSE in patients with advanced non-small cell lung cancer. , 2004, Respiratory medicine.

[34]  Jeffrey S. Morris,et al.  Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments , 2004, Bioinform..

[35]  D. Chan,et al.  Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.

[36]  O. John Semmes,et al.  SELDI-TOF Serum Profiling for Prognostic and Diagnostic Classification of Breast Cancers , 2004, Disease markers.

[37]  X. Xiao,et al.  Development of Proteomic Patterns for Detecting Lung Cancer , 2004, Disease markers.

[38]  John R Yates,et al.  Reproducibility of quantitative proteomic analyses of complex biological mixtures by multidimensional protein identification technology. , 2003, Analytical chemistry.

[39]  Peter F M Choong,et al.  Urokinase plasminogen activator system: a multifunctional role in tumor progression and metastasis. , 2003, Clinical orthopaedics and related research.

[40]  Stephen Russell,et al.  High‐throughput proteomic analysis of human infiltrating ductal carcinoma of the breast , 2003, Proteomics.

[41]  T. Zhukov,et al.  Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. , 2003, Lung cancer.

[42]  Zhao Rui,et al.  Use of serological proteomic methods to find biomarkers associated with breast cancer , 2003, Proteomics.

[43]  V. Santoni,et al.  Evaluation of nonionic and zwitterionic detergents as membrane protein solubilizers in two‐dimensional electrophoresis , 2003, Proteomics.

[44]  Kathleen N Lohr,et al.  Screening for Prostate Cancer: An Update of the Evidence for the U.S. Preventive Services Task Force , 2002, Annals of Internal Medicine.

[45]  J. Yates,et al.  Shotgun Proteomics and Biomarker Discovery , 2002, Disease markers.

[46]  E. Petricoin,et al.  Serum proteomic patterns for detection of prostate cancer. , 2002, Journal of the National Cancer Institute.

[47]  Dirk Wolters,et al.  Proteomic survey of metabolic pathways in rice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[48]  O John Semmes,et al.  Normal, benign, preneoplastic, and malignant prostate cells have distinct protein expression profiles resolved by surface enhanced laser desorption/ionization mass spectrometry. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[49]  D. Chan,et al.  Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. , 2002, Clinical chemistry.

[50]  T. Čufer,et al.  Prognostic value of the urokinase-type plasminogen activator, and its inhibitors and receptor in breast cancer patients. , 2002, Clinical breast cancer.

[51]  S. Varnum,et al.  Elevated HGF levels in sera from breast cancer patients detected using a protein microarray ELISA. , 2002, Journal of proteome research.

[52]  K. Lillemoe,et al.  Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.

[53]  M. Mrksich,et al.  Peptide chips for the quantitative evaluation of protein kinase activity , 2002, Nature Biotechnology.

[54]  E. Petricoin,et al.  Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.

[55]  Rainer Cramer,et al.  Evaluation of Two-dimensional Differential Gel Electrophoresis for Proteomic Expression Analysis of a Model Breast Cancer Cell System* , 2002, Molecular & Cellular Proteomics.

[56]  Kathryn S Lilley,et al.  Two-dimensional gel electrophoresis: recent advances in sample preparation, detection and quantitation. , 2002, Current opinion in chemical biology.

[57]  N. Fedarko,et al.  Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[58]  S. Hanash,et al.  Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. , 2001, Cancer research.

[59]  S M Hanash,et al.  Protein based microarrays: A tool for probing the proteome of cancer cells and tissues , 2001, Proteomics.

[60]  E. Petricoin,et al.  Reverse phase protein microarrays which capture disease progression show activation of pro-survival pathways at the cancer invasion front , 2001, Oncogene.

[61]  Tzei-Yi Lin,et al.  Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. , 2001, Cancer research.

[62]  P. Ravdin,et al.  Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  M. Mann,et al.  Analysis of proteins and proteomes by mass spectrometry. , 2001, Annual review of biochemistry.

[64]  A. Nakao,et al.  PGP9.5 as a prognostic factor in pancreatic cancer. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[65]  Jean-Charles Sanchez,et al.  Proteomics: new perspectives, new biomedical opportunities , 2000, The Lancet.

[66]  A. Bozdağ,et al.  The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. , 2000, Hepato-gastroenterology.

[67]  S. Gygi,et al.  Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[68]  G. Sakorafas,et al.  Molecular biology of pancreatic cancer; oncogenes, tumour suppressor genes, growth factors, and their receptors from a clinical perspective. , 2000, Cancer treatment reviews.

[69]  H. Ge,et al.  UPA, a universal protein array system for quantitative detection of protein-protein, protein-DNA, protein-RNA and protein-ligand interactions. , 2000, Nucleic acids research.

[70]  L. G. Mendoza,et al.  High-throughput microarray-based enzyme-linked immunosorbent assay (ELISA). , 1999, BioTechniques.

[71]  S. Gygi,et al.  Quantitative analysis of complex protein mixtures using isotope-coded affinity tags , 1999, Nature Biotechnology.

[72]  J. Jen,et al.  Serial analysis of gene expression in non-small cell lung cancer. , 1998, Cancer research.

[73]  T. Turpeenniemi‐Hujanen,et al.  Matrix metalloproteinase‐2 immunoreactive protein , 1998, Cancer.

[74]  A. Ishida,et al.  Analysis of protein-protein interaction by two-dimensional affinity electrophoresis. , 1998, Analytical biochemistry.

[75]  J. Foekens,et al.  Prognostic significance of cathepsins B and L in primary human breast cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  M. Ünlü,et al.  Difference gel electrophoresis. A single gel method for detecting changes in protein extracts , 1997, Electrophoresis.

[77]  Julian Peto,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1996, Nature.

[78]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[79]  B. Têtu,et al.  Prognostic significance of HER‐2/neu oncoprotein expression in node‐positive breast cancer. The influence of the pattern of immunostaining and adjuvant therapy , 1994, Cancer.

[80]  G. Hortobagyi,et al.  Ki‐67 immunostaining in node‐negative stage I/II breast carcinoma. Significant correlation with prognosis , 1991, Cancer.

[81]  J. Schulte‐Mönting,et al.  Ki‐67 immunostaining in human breast tumors and its relationship to prognosis , 1991, Cancer.

[82]  G M Clark,et al.  How to use prognostic factors in axillary node-negative breast cancer patients. , 1990, Journal of the National Cancer Institute.

[83]  W. Steinberg.  The clinical utility of the CA 19-9 tumor-associated antigen. , 1990, The American journal of gastroenterology.

[84]  D. Pleskow,et al.  Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. , 1989, Annals of internal medicine.

[85]  J. Polak,et al.  Immunohistochemical markers of small cell carcinoma and related neuroendocrine tumours of the lung , 1987, The Journal of pathology.

[86]  E. Rowińska-Zakrzewska,et al.  [Value of the determination of carcinoembryonic antigen (CEA) in the serum for the diagnosis of lung cancer; evaluation of its extent and prognosis in conservatively treated patients]. , 1984, Pneumonologia polska.

[87]  Phil Gold,et al.  DEMONSTRATION OF TUMOR-SPECIFIC ANTIGENS IN HUMAN COLONIC CARCINOMATA BY IMMUNOLOGICAL TOLERANCE AND ABSORPTION TECHNIQUES , 1965, The Journal of experimental medicine.